Cxcr5 receptor compounds

A compound represented by Formula B or a pharmaceutically acceptable salt thereof:

• T-L-Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15-
• Y16-Y17-Y18-Y19-Y20-Y21-Y22-Y23-Y24-Y25-R1;
• wherein L is a linking moiety represented by C(O) and bonded the N terminal nitrogen of Y1 or the next present amino acid residue if Y1 is absent, T is a lipophilic tether moiety bonded to L;
• and R1 is OR2 or N(R2)2, wherein each R2 is independently H or alkyl, wherein at least three contiguous Y1Y25 amino acid residues are present, and wherein:
• Yi is a leucine residue or absent,
• Y2 is an alanine residue or absent,
• Y3 is an isoleucine residue or absent,
• Y4 is a valine residue or absent,
• Y5 is a histidine residue, alanine residue or absent,
• Y6 is an alanine residue or absent,
• Y7 is a valine residue or absent,
• Y8 is a histidine residue,
• Y9 is an alanine residue,
• Y10 is a tyrosine residue,
• Y11 is an arginine residue,
• Y12 is a histidine residue,
• Y13 is an arginine residue,
• Y14 is an arginine residue,
• Yis is a leucine residue or absent,
• Y16 is a leucine residue or absent,
• Y17 is a serine residue or absent,
• Y18 is an isoleucine residue or absent,
• Y19 is a histidine residue or absent,
• Y20 is an isoleucine residue or absent, and
• Y21 is a threonine or residue absent.

A compound represented by Formula C or a pharmaceutically acceptable salt thereof, wherein:

• T-L-W1-W2-W3-W4-W5-W6-W7-W8-W9-W10-W11-W12-W13-W14-W15-
• W16-W17-W18-W19-W20-W21-W22-W23-R1;
• wherein L is a linking moiety represented by C(O) and bonded to the N terminal nitrogen of W1 or the next present amino acid residue if W1 is absent;
• T is a lipophilic tether moiety bonded to L;
• and R1 is OR2 or N(R2)2, wherein each R2 is independently H or alkyl, wherein at least three contiguous W1-W23 amino acid residues are present and wherein:
• W1 is a glycine residue, a histidine residue or absent,
• W2 is a valine, a phenylalanine residue, a glycine residue or absent,
• W3 is a valine residue, an arginine residue, a serine residue or absent,
• W4 is a histidine residue, a lysine residue, a glycine residue or absent,
• W5 is an arginine residue, a glutamic residue acid or absent,
• W6 is a leucine residue, an arginine residue or absent,
• W7 is an arginine residue, an isoleucine residue or absent,
• W8 is a glutamine residue, a glutamic acid residue, an asparagine residue, a threonine residue or absent,
• W9 is an alanine residue, a glycine residue or absent,
• W10 is a glutamine residue, a leucine residue, an asparagine residue, a threonine residue or absent,
• W11 is an arginine residue or absent,
• W12 is an arginine residue or lysine,
• W13 is a proline residue or arginine,
• W14 is a glutamine residue, an arginine residue, an asparagine residue or a threonine residue,
• W15 is an arginine residue,
• W16 is a glutamine residue, a leucine residue, an asparagine residue, a threonine residue or absent,
• W17 is a lysine residue or absent,
• W18 is an alanine residue or absent,
• W19 is a valine residue or absent,
• W20 is an arginine residue or absent,
• W21 is a valine residue or absent,
• W22 is an alanine residue or absent, and
• W23 is an isoleucine residue or absent.

A compound represented by Formula D or a pharmaceutically acceptable salt thereof:

• T-L-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-Z12-Z13-Z14-Z15-
• Z16-Z17-Z18-Z19-Z20-Z21-Z22-Z23-Z23-Z24-Z25-Z26-Z27-Z28-
• Z29Z30-Z31Z32-Z33-Z34-Z35-Z36-Z37-Z38-Z39-Z40-Z41-Z42-Z43-
• Z44-Z45-Z46-Z47-Z48-R1;
• wherein L is a linking moiety represented by C(O) and bonded to the N terminal nitrogen of Z1 or the next present amino acid if Z1 is absent;
• T is a lipophilic tether moiety bonded to L;
• and R1 is OR2 or N(R2)2, wherein each R2 is independently H or alkyl, wherein at least three contiguous Z1-Z23 amino acid residues are present and wherein:
• Z1 is an alanine residue or absent,
• Z2 is a glycine residue or absent,
• Z3 is a valine residue, or absent,
• Z4 is a lysine residue or absent,
• Z5 is a phenylalanine residue or absent,
• Z6 is an arginine residue or absent,
• Z7 is a serine residue or absent,
• Z8 is an aspartic acid residue or absent,
• Z9 is a leucine residue or absent,
• Z10 is a serine residue or absent,
• Z11 is an arginine residue or absent,
• Z12 is a leucine residue,
• Z13 is a leucine residue or arginine,
• Z14 is a threonine residue,
• Z15 is a lysine residue,
• Z16 is a leucine residue or absent,
• Z17 is a glycine residue or absent,
• Z18 is a cysteine residue, a serine residue or absent,
• Z19 is a threonine residue or absent,
• Z20 is a glycine or absent residue or absent,
• Z21 is a proline residue or absent,
• Z22 is an alanine residue or absent,
• Z23 is a serine residue or absent,
• Z24 is a leucine residue or absent,
• Z25 is a cysteine residue, a serine residue or absent,
• Z26 is a glutamine residue or absent,
• Z27 is a leucine residue or absent,
• Z28 is a phenylalanine residue or absent,
• Z29 is a proline residue or absent,
• Z30 is a serine residue or absent,
• Z31 is a tryptophan residue or absent,
• Z32 is an arginine residue or absent,
• Z33 is an arginine residue or absent,
• Z34 is a serine residue or absent,
• Z35 is a serine residue or absent,
• Z36 is a leucine residue or absent,
• Z37 is a serine residue or absent,
• Z38 is a glutamic residue acid or absent,
• Z39 is a serine residue or absent,
• Z40 is a glutamic residue acid or absent,
• Z41 is an asparagine residue or absent,
• Z42 is a alanine residue or absent,
• Z43 is a threonine residue or absent,
• Z44 is a serine residue or absent,
• Z45 is a leucine residue or absent,
• Z46 is a threonine residue or absent,
• Z47 is a threonine residue or absent, and
• Z48 is a phenylalanine residue or absent.

A compound represented by Formula I:

• T-L-P,
• or a pharmaceutically acceptable salt thereof, wherein:
• P is a peptide sequence selected from:
• SEQ ID NOS:
• 1-93;
• L is a linking moiety represented by C(O) and bonded to P at an N terminal nitrogen of an N-terminal amino-acid residue;
• and T is a lipophilic tether moiety bonded to L.